Center of Research on Psychology in Somatic Diseases, Department of Medical Psychology, Tilburg University, Tilburg, The Netherlands.
BJU Int. 2011 Apr;107(8):1223-31. doi: 10.1111/j.1464-410X.2010.09861.x. Epub 2010 Nov 11.
Study Type--Therapy (outcomes research) Level of Evidence 2b. What's known on the subject? and What does the study add? Comorbid diabetes can affect prostate cancer treatment decision-making and outcomes. Few longitudinal studies have investigated the effect of comorbid diabetes on general and cancer-specific health-related quality of life (HRQL) in prostate cancer. Our study found that men with prevalent diabetes (pre-prostate cancer diagnosis) generally had the poorest general HRQL, urinary control and sexual function scores over time, independent of treatment. Non-diabetic men had the best scores and men with incident diabetes (post-prostate cancer diagnosis) reported intermediate scores. OBJECTIVE • To investigate the association between prostate cancer, diabetes, and long-term general and cancer-specific health-related quality of life (HRQL) in a cohort of men with non-metastatic prostate cancer. PATIENTS AND METHODS • We used data from self-administered surveys to assess the HRQL of men with localized or locally advanced disease at 6 (baseline), 12, 24, and 60 months after initial diagnosis. • We examined changes in general and cancer-specific HRQL with repeated measures analyses using a mixed-model approach. RESULTS • In total, we evaluated 1811 men, including 13% with prevalent (pre-prostate cancer diagnosis) diabetes, 12% with incident (post-prostate cancer diagnosis) diabetes, and 75% who never reported being diagnosed with diabetes. • Generally, men with prevalent diabetes had the poorest scores on general HRQL and non-diabetic men the best scores, independent of treatment. • Similarly, men with prevalent diabetes had the lowest urinary control and sexual function scores over time, while men without diabetes had the highest scores. Men with incident diabetes reported intermediate scores. CONCLUSION • Prostate cancer survivors with comorbid diabetes have poorer general and cancer-specific HRQL than those without diabetes.
研究类型——治疗（结局研究）证据水平 2b. 已知主题的相关信息是什么？本研究有何补充？合并糖尿病会影响前列腺癌的治疗决策和结局。少数纵向研究调查了合并糖尿病对前列腺癌患者一般和癌症特异性健康相关生活质量（HRQL）的影响。我们的研究发现，患有糖尿病（前列腺癌诊断前）的男性在前列腺癌诊断后，无论治疗方式如何，其一般 HRQL、尿控和性功能评分通常最差。非糖尿病男性的评分最好，而新发糖尿病（前列腺癌诊断后）的男性报告的评分则处于中等水平。目的：探讨非转移性前列腺癌患者中前列腺癌、糖尿病与长期一般和癌症特异性健康相关生活质量（HRQL）之间的关联。患者和方法：我们使用自我管理的问卷调查来评估局部或局部晚期疾病患者的 HRQL，在初始诊断后 6 个月（基线）、12 个月、24 个月和 60 个月进行评估。我们使用混合模型方法，通过重复测量分析来评估一般和癌症特异性 HRQL 的变化。结果：我们共评估了 1811 名男性，其中 13%患有合并症（前列腺癌诊断前）糖尿病，12%患有（前列腺癌诊断后）新发糖尿病，75%从未被诊断为糖尿病。一般来说，患有合并症糖尿病的男性的一般 HRQL 评分最差，而非糖尿病男性的评分最好，且这种情况与治疗方式无关。同样，随着时间的推移，患有合并症糖尿病的男性的尿控和性功能评分最低，而没有糖尿病的男性的评分最高。患有新发糖尿病的男性报告的评分处于中等水平。结论：患有合并症糖尿病的前列腺癌幸存者的一般和癌症特异性 HRQL 比没有糖尿病的患者差。
